AKBA - CIK 0001517022
The table below shows Akebia Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $184.84M | $51.87M | $42.92M | $90.47M | $149.80M | $228.70M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $47.03M | $34.37M | $39.29M | $39.18M | $50.88M | $26.85M |
| Inventory | $15.61M | $16.24M | $15.69M | $21.76M | $38.20M | $61.02M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $252.96M |
| $113.83M |
| $118.15M |
| $185.18M |
| $272.01M |
| $371.44M |
| Property, plant & equipment | $1.22M | $2.20M | $3.63M | $5.21M | $6.75M | $8.62M |
| Goodwill | $59.04M | $59.04M | $59.04M | $55.05M | $55.05M | $55.05M |
| Total assets | $376.56M | $220.67M | $241.70M | $356.05M | $525.55M | $644.14M |
| Accounts payable | $21.18M | $15.18M | $14.63M | $18.02M | $33.59M | $41.31M |
| Total current liabilities | $162.94M | $80.91M | $99.87M | $129.54M | $256.49M | $187.15M |
| Long-term debt | $48.25M | $38.69M | $17.18M | $34.08M | $0.00 | $96.38M |
| Total liabilities | $343.95M | $269.86M | $272.29M | $350.82M | $449.09M | $396.52M |
| Retained earnings | -$1.68B | -$1.68B | -$1.61B | -$1.55B | -$1.46B | -$1.18B |
| Total equity | $32.61M | -$49.19M | -$30.58M | $5.23M | $76.46M | $247.62M |